Invega Sustenna — Competitive Intelligence Brief

Invega Sustenna (PALIPERIDONE PALMITATE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical Antipsychotic. Area: Metabolic.

marketed Atypical Antipsychotic Potassium voltage-gated channel subfamily H member 2 Metabolic Small molecule

Target snapshot

Invega Sustenna (PALIPERIDONE PALMITATE) — Johnson & Johnson. Invega Sustenna works by blocking a specific channel in the brain that helps regulate electrical activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Invega Sustenna TARGET	PALIPERIDONE PALMITATE	Johnson & Johnson	marketed	Atypical Antipsychotic	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Rukobia	FOSTEMSAVIR	GSK	marketed		Potassium voltage-gated channel subfamily H member 2	2020-01-01
Daklinza	DACLATASVIR	Bristol-Myers Squibb	marketed	Hepatitis C Virus NS5A Inhibitor	Potassium voltage-gated channel subfamily H member 2	2015-01-01
Sirturo	bedaquiline	Janssen Therap	marketed	Diarylquinoline Antimycobacterial	Potassium voltage-gated channel subfamily H member 2	2012-01-01
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Ketek	TELITHROMYCIN	Sanofi	marketed	Ketolide Antibacterial	Potassium voltage-gated channel subfamily H member 2	2004-01-01
Trisenox	ARSENIC TRIOXIDE	Cephalon	marketed	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2	2000-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical Antipsychotic class)

1. Acadia Pharms Inc · 1 drug in this class
2. Johnson & Johnson · 1 drug in this class
3. Sunovion Pharms Inc · 1 drug in this class